HeartBeam, Inc. (BEAT)
| Market Cap | 28.34M -24.9% |
| Revenue (ttm) | n/a |
| Net Income | -20.30M |
| EPS | -0.50 |
| Shares Out | 56.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 393,332 |
| Open | 0.4832 |
| Previous Close | 0.4832 |
| Day's Range | 0.4801 - 0.5160 |
| 52-Week Range | 0.4710 - 4.0000 |
| Beta | -0.79 |
| Analysts | Strong Buy |
| Price Target | 3.38 (+571.97%) |
| Earnings Date | Aug 13, 2026 |
About BEAT
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility. The company develops HeartBeam System, a cable-free and ambulatory 12L ECG that captures the heart’s electrical signals from three dimensions for high-fidelity data collection and advanced diagnostics for arrhythmia assessment which consists of credit card sized 3D ECG recording device, a patient application, a physician port... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for BEAT stock is "Strong Buy." The 12-month stock price target is $3.38, which is an increase of 571.97% from the latest price.
News
HeartBeam reports Q2 EPS (10c) vs (15c) last year
“Every 40 seconds, someone suffers from a heart attack, and we believe HeartBeam’s (BEAT) technology, incorporating our signal capture technology TriCor, is the best way to evaluate the real extent…
HeartBeam sees Q3 cash flow in line with Q2
Third quarter 2026 cash outflow is expected to be in line with the second quarter of 2026, due to the short-term impact of updating the Company’s cost structure. Baseline fourth…
HeartBeam Earnings Call Transcript: Q2 2026
Heart attack detection initiatives advanced with FDA pre-submission and strong clinical validation. Operating cash outflows and net loss decreased, with commercial rollout gaining traction in key U.S. markets and cash runway extended into 2027.
HeartBeam Quarterly report: Q2 2026
HeartBeam has published its Q2 2026 quarterly earnings report on August 13, 2026.
HeartBeam Slides: Q2 2026
HeartBeam has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
HeartBeam Earnings release: Q2 2026
HeartBeam released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
HeartBeam Reports Second Quarter 2026 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Second Quarter 2026 Results.
HeartBeam Transcript: AGM 2026
The meeting confirmed a quorum, elected seven directors, and approved the auditor for 2026. The proposal to amend the equity plan was not approved. Shareholders were directed to the website for further updates and a quarterly call in August.
HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time.
HeartBeam initiated with a Buy at Maxim
Maxim initiated coverage of HeartBeam (BEAT) with a Buy rating and $2 price target
HeartBeam awarded U.S. patent for ECG device capabilities
HeartBeam (BEAT) announced the allowance of a new U.S. patent that significantly expands the capabilities of its credit card-sized, cable-free ECG device. The patent covers the integration of acoustic...
HeartBeam completes patient enrollment in ALIGN-ACS pilot study
HeartBeam (BEAT) announced completion of patient enrollment in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. Enrollment was completed ahead of the Company’s pre...
HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule.
HeartBeam Proxy statement: Proxy filing
HeartBeam filed a proxy statement on June 25, 2026, providing details for shareholder voting and corporate governance matters.
HeartBeam announces strategic shift to ambulatory ECG signal platform
The company states: “HeartBeam (BEAT) announced a reorganization to prioritize global market reach and capital efficiency while accelerating execution. The company has aligned its operations around fo...
HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition.
HeartBeam Proxy statement: Proxy filing
HeartBeam filed a proxy statement on June 18, 2026, providing details for shareholder voting and corporate governance matters.
HeartBeam Proxy statement: Proxy filing
HeartBeam filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.
HeartBeam Slides: Investor presentation
HeartBeam has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.
HeartBeam announces peer-reviewed article in JACC on HeartBeam ECG
HeartBeam (BEAT) announced a peer-reviewed article in JACC: Advances, a journal of the American College of Cardiology, demonstrating that a risk prediction algorithm incorporating the credit card-size...
HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home.
HeartBeam price target lowered to $2.50 from $5.50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on HeartBeam (BEAT) to $2.50 from $5.50 and keeps a Buy rating on the shares post the Q1 report. The firm believes the…
HeartBeam price target lowered to $5 from $8 at Benchmark
Benchmark lowered the firm’s price target on HeartBeam (BEAT) to $5 from $8 and keeps a Speculative Buy rating on the shares after “a solid update” provided with Q1 results.
HeartBeam Earnings Call Transcript: Q1 2026
Achieved key milestones in commercialization, clinical validation, and product development, including flagship accounts in four major geographies and a strategic AI partnership. Q1 2026 saw a 19% year-over-year reduction in cash burn, with a strengthened balance sheet and funding runway into 2027.
HeartBeam Quarterly report: Q1 2026
HeartBeam has published its Q1 2026 quarterly earnings report on May 13, 2026.